Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Platelet-Rich Plasma vs. Mesenchymal Stem Cells for Lumbar Disc Degeneration: A Systematic Review and Meta-Analysis

Salamanna F., Ghermandi R., Veronesi F., Borsari V., Griffoni C., Gasbarrini A.

Meta-analysis on Disc Degeneration, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Int J Mol Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42123394
PMCID
PMC13164523
DOI
10.3390/ijms27093810

Abstract (original English)

Platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) are promising regenerative treatments for lumbar degenerative disc disease (DDD), but their comparative efficacy is unclear. This systematic review and indirect meta-analysis, conducted according to PRISMA guidelines and the PICOS framework, evaluated their effects on pain, function, and safety. PubMed, Scopus, and Web of Science were systematically searched, yielding 1694 records, of which 21 studies (nine randomized controlled trials [RCTs] and 12 prospective studies) were included. Data were analyzed qualitatively and quantitatively, and risk of bias was assessed using RoB 2 and ROBINS-I. Meta-analyses of randomized controlled trials (RCTs) examined pain and disability at 6 and 12 months using a random-effects model. Indirect comparisons were performed using the Bucher method. Qualitative synthesis showed that PRP consistently reduced pain (often > 50%) and improved function, frequently outperforming corticosteroids. MSCs provided sustained benefits, with follow-up extending up to 72 months in some studies. Quantitative meta-analysis of five RCTs demonstrated that PRP significantly reduced pain at 6 months (mean difference [MD] -16.4 mm) and disability (ODI -12.7), with effects persisting at 12 months in one study. In contrast, MSCs showed a modest but significant reduction in pain (MD -4.3 mm) and minimal function

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Lumbar VertebraeMesenchymal Stem CellsHumansTreatment OutcomeMesenchymal Stem Cell TransplantationPlatelet-Rich PlasmaRandomized Controlled Trials as TopicIntervertebral Disc Degeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research